LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East

Core Insights - LENZ Therapeutics has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting for the commercialization of VIZZ in the Middle East, which includes revenue sharing and milestone payments [1][2][3] Company Overview - LENZ Therapeutics is focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first FDA-approved eye drop for presbyopia, impacting approximately 1.8 billion people globally and 128 million in the U.S. [9] - Lunatus is a Dubai-based pharmaceutical company specializing in the commercialization of healthcare products in the Middle East, established in 2003 [10] Product Information - VIZZ is a once-daily eye drop designed to restore clear near vision for up to 10 hours, utilizing aceclidine as the active ingredient [5] - The product is preservative-free and provided in single-dose vials, offering a pupil-selective miotic effect to improve vision [5] Market Context - The partnership with Lunatus represents LENZ's fourth commercialization partnership for VIZZ, aimed at expanding access to presbyopia treatment in key strategic regions [3] - Presbyopia affects nearly all individuals over the age of 45, with adults over 50 losing an average of 1.5 lines of near vision every six years [4]